Eisai Co., Ltd. announced that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima, "lenvatinib", kinase inhibitor), eribulin mesylate (product name: Halaven, "eribulin", halichondrin class microtubule dynamics inhibitor), and MORAb-202 (antibody drug conjugate, ADC) will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019. 

The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor covalent antagonist), which were discovered by Eisai's U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.

Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. MORAb-202 is a novel ADC that combines Eisai's investigational anti-folate receptor (FRA) antibody farletuzumab with Eisai's in-house discovered anticancer agent eribulin as the payload.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.